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Abstract
Alkaptonuria (AKU) is caused by homogentisate 1,2-dioxygenase deficiency that
leads to homogentisic acid (HGA) accumulation, ochronosis and severe oste-
oarthropathy. Recently, nitisinone treatment, which blocks HGA formation, has
been effective in AKU patients. However, a consequence of nitisinone is elevated
tyrosine that can cause keratopathy. The effect of tyrosine and phenylalanine dietary
restriction was investigated in nitisinone-treated AKU mice, and in an observational
study of dietary intervention in AKU patients. Nitisinone-treated AKU mice were
fed tyrosine/phenylalanine-free and phenylalanine-free diets with phenylalanine sup-
plementation in drinking water. Tyrosine metabolites were measured pre-nitisinone,
post-nitisinone, and after dietary restriction. Subsequently an observational study
was undertaken in 10 patients attending the National Alkaptonuria Centre (NAC),
with tyrosine >700 μmol/L who had been advised to restrict dietary protein intake
and where necessary, to use tyrosine/phenylalanine-free amino acid supplements.
Elevated tyrosine (813 μmol/L) was significantly reduced in nitisinone-treated AKU
mice fed a tyrosine/phenylalanine-free diet in a dose responsive manner. At 3 days
of restriction, tyrosine was 389.3, 274.8, and 144.3 μmol/L with decreasing phenyl-
alanine doses. In contrast, tyrosine was not effectively reduced in mice by a
phenylalanine-free diet; at 3 days tyrosine was 757.3, 530.2, and 656.2 μmol/L, with
no dose response to phenylalanine supplementation. In NAC patients, tyrosine was
significantly reduced (P = .002) when restricting dietary protein alone, and when
combined with tyrosine/phenylalanine-free amino acid supplementation; 4 out of
10 patients achieved tyrosine <700 μmol/L. Tyrosine/phenylalanine dietary restric-
tion significantly reduced nitisinone-induced tyrosinemia in mice, with phenylala-
nine restriction alone proving ineffective. Similarly, protein restriction significantly
reduced circulating tyrosine in AKU patients.
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1 | INTRODUCTION
Alkaptonuria (AKU; OMIM #203500) is an autosomal reces-
sive, multisystem disease caused by mutations in the hom-
ogentisate 1,2-dioxygenase (HGD) enzyme (EC 1.13.11.5).1
HGD deficiency leads to homogentisic acid (HGA) accumu-
lation (Figure 1A) in the blood and tissues. Over time, excess
HGA forms a dark brown ochronotic pigment that deposits in
connective tissues causing them to become stiff and brittle,2-5
leading to early-onset and severe osteoarthropathy.
Recently, a drug called nitisinone (2-(2-nitro-
4-[trifluoromethyl]benzoyl)cyclohexane-1,3-dione; NTBC) that
blocks 4-hydroxyphenylpyruvic acid dioxygenase (HPPD; EC
1.13.11.27) which converts 4-hydroxyphenylpyruvic acid
(HPPA) into HGA was shown to prevent ochronosis in AKU
mice,6,7 leading to a series of human clinical trials assessing
nitisinone in AKU.8 The SONIA-1 trial concluded that
nitisinone effectively reduces HGA to a level likely to prevent
ochronosis.8 However, increased serum tyrosine was seen with
nitisinone treatment.8
Elevated serum tyrosine (tyrosinemia) causes eye and
skin keratopathy in nitisinone-treated hereditary tyrosinemia
type 1 (HT-1; OMIM #276700),9 resembling the dermal and
ocular symptoms seen in hereditary tyrosinemia type II
(OMIM #276600).10 Low-dose nitisinone (0.5 mg daily) in
an AKU patient has induced ocular irritation and photopho-
bia that presented before corneal crystal deposition.11 More
worryingly, a study reported mild corneal keratopathy in an
AKU patient on 2 mg of nitisinone daily with no ocular
symptoms or pain.12 This is concerning as untreated
keratopathy could be sight-threatening if not detected.
Moreover, the association of tyrosinemia with neural
cognition is another important consideration, as tyrosine is a
precursor to neurotransmitters such as dopamine, adrenaline
and noradrenaline. Metabolites of these neurotransmitters
have previously been shown to significantly alter with
nitisinone treatment in AKU patients.13 Similarly, numerous
reports and studies document impaired cognitive function in
HT-1 patients that have been treated long-term with
nitisinone and protein restriction.9,14,15 These neu-
rodevelopmental effects however could be due to either
nitisinone-induced tyrosinemia or severe liver failure experi-
enced before diagnosis and subsequent initiation of
nitisinone treatment. With the cause of impaired cognition in
HT-1 remaining to be elucidated, the off-license use of
nitisinone has been restricted to ≥16 years in AKU.
A tyrosine-lowering strategy that can prevent keratopathy,
such as protein/tyrosine restriction, is implemented in con-
junction with nitisinone treatment in HT-1.16,17 However,
poor adherence to protein supplements coupled with an inade-
quate low protein diet, can lead to essential amino acid and
micronutrient deficiency.18,19 Although advised, no clinical
study has investigated the effectiveness of dietary restriction
at reducing nitisinone-induced tyrosinemia in AKU.
Here, dietary restriction of tyrosine and phenylalanine
was investigated in nitisinone-treated AKU mice to establish
its effectiveness at reducing tyrosinemia. Additional obser-
vational data of dietary intervention in AKU patients attend-
ing the National Alkaptonuria Centre (NAC; Liverpool,
UK), where patients receive 2 mg nitisinone daily, are pres-
ented. At the NAC, serum tyrosine increases to a mean level
of approximately 600 to 700 μmol/L20,21 with nitisinone,
therefore patients are advised to restrict protein intake with
guidance from a specialist dietician. We provide proof-of-
concept that mechanisms reducing uptake of dietary tyrosine
into the bloodstream would be effective.
2 | METHODS
2.1 | Mice
BALB/c Hgd−/− mice,7 referred to as AKU, were all
housed and maintained within the University of Liverpool
Biological Services Unit in specific pathogen-free conditions
in accordance with Home Office UK guidelines. Food and
water were available ad libitum.
2.2 | Dietary restriction studies
To investigate tyrosine and phenylalanine dietary restriction
on nitisinone-induced tyrosinemia and on other tyrosine
FIGURE 1 Tyrosine metabolism pathway. Enzymes are in
italics. Disorders are in boxes. NTBC (nitisinone) inhibits
4-hydroxyphenylpyruvic acid dioxygenase
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pathway metabolites, AKU mice (n = 6; three male, three
female) were treated with nitisinone for 1 week on normal
diet, then switched to either tyrosine/phenylalanine-free or
phenylalanine only-free diets with phenylalanine sup-
plemented into the drinking water to investigate dose
response, while still on nitisinone. Controls remained on
normal diet. Blood samples were taken pre-nitisinone,
1 week post-nitisinone and then during dietary restriction.
2.3 | Diets
The normal control mouse diet (CRM(P), product code
801722, Special Diet Services [SDS], UK), contained 0.88%
phenylalanine and 0.59% tyrosine. Restricted diets were syn-
thetically made by SDS in pellet form. Synthetic raw mate-
rials were used to produce an amino acid defined diet which
has an amino acid profile similar to the normal CRM(P) diet,
with tyrosine and/or phenylalanine removed and balanced
on maize starch.
2.4 | Nitisinone and phenylalanine provision
in drinking water
Nitisinone was added to the drinking water at 4 mg/L
(0.8 mg/kg; based on a 30 g mouse drinking approximately
6 mL/day) and was freely available. Phenylalanine was
added to the drinking water at various doses, between 0 and
5 mg/mL as indicated in the results.
2.5 | Calculating dietary restriction
Daily food and water intake is approximately 5 g and 6 mL
respectively, per 30 g bodyweight for the BALB/cByJ
strain.22 A 30 g mouse on the normal CRM(P) diet therefore
consumes approximately 44 mg/day phenylalanine and
29.5 mg/day tyrosine. In the tyrosine/phenylalanine-free diet
study, drinking water was supplemented with 5, 2.5, and
1.25 mg/mL phenylalanine, equating to approximately 68%
phenylalanine/0% tyrosine, 34% phenylalanine/0% tyrosine
and 17% phenylalanine/0% tyrosine, respectively. In the phe-
nylalanine free diet study, drinking water was supplemented
with 2.5, 0.625, and 0 mg/mL phenylalanine, equating to
approximately 34% phenylalanine/100% tyrosine, 8.5% phe-
nylalanine/100% tyrosine and 0% phenylalanine/100% tyro-
sine, respectively.
2.6 | Blood collection from mice
Acidified plasma from venous tail bleeds was collected to
analyze tyrosine pathway metabolites via HPLC tandem
mass spectrometry.23
2.7 | NAC patients
NAC patients receive off-license treatment of 2 mg
nitisinone daily, dietary advice and have serum tyrosine
monitored at yearly visits.21 The NAC aims to achieve tyro-
sine <500 μmol/L. Tyrosine thresholds of 500 to
700 μmol/L and 700 to 900 μmol/L are used as guidelines
for reducing dietary protein consumption to 0.9 and 0.8 g
protein/kg bodyweight/day, respectively. Patients with tyro-
sine >700 μmol/L are more closely monitored with addi-
tional blood sampling if required. Fasting blood samples
were taken in the morning. Ten anonymized NAC patients
with tyrosine >700 μmol/L are reported here. All patients
received advice to reduce dietary protein intake to a rec-
ommended minimum level of 0.75 g protein/kg
bodyweight/day, to reduce circulating tyrosine while meet-
ing minimum nutritional requirements. A TYR cooler
(Vitaflo, UK) protein substitute (free in
tyrosine/phenylalanine) drink was used by seven of
10 patients. TYR cooler dosage was determined by the dieti-
cian for each individual; protein removed from the diet,
below the recommended minimum, was exchanged for the
equivalent amount of protein in the cooler. These patients
had been attending the NAC for a mean of 36.5 months
(range 29-48) at the initial tyrosine concentration, with a
mean age of 56 years (range 29-71). The gender of patients
was five male, five female. Eight were white British, one
was Indian, and one was Pakistani.
2.8 | Statistical analysis
Statistical analysis was performed using Stats Direct 3 statis-
tical software (England, UK). Means are represented as
mean ± SE on the mean (SEM). Statistical significance,
using α = 0.05; *P < .05; **P < .01; ***P < .001. Error
bars represent SEM.
3 | RESULTS
3.1 | Effect of nitisinone treatment on tyrosine
pathway metabolites
Tyrosine pathway metabolites were measured in the plasma
of 24 AKU mice pre- and post-nitisinone treatment (4 mg/L
in drinking water for 7 days) (Figure 2B). HGA was signifi-
cantly decreased 8-fold from 255.1 ± 43.2 to 32.9 ±
3.2 μmol/L while all other metabolites increased; all changes
were significant (P < .001, two-tailed paired t test). Tyrosine
increased 11-fold from 72.9 ± 3.6 μmol/L to 813.3 ±
37.6 μmol/L. Phenylalanine increased 1.5-fold from 67.3 ±
2.4 to 100.8 ± 4.9 μmol/L. HPPA increased 14.5-fold from
10.5 ± 0.4 to 151.8 ± 12.9 μmol/L. 4-hydroxyphenyllactic
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FIGURE 2 Dietary restriction of tyrosine and phenylalanine in NTBC-treated AKU mice. A, shows when blood samples were taken and when
diet conditions were altered. B, shows plasma metabolite levels before NTBC treatment (all mice; n = 24), after 1 week of NTBC treatment (all
mice; n = 24), then after 3 (n = 6) and 14 days (n = 6) of tyrosine/phenylalanine restriction. C, shows the change in bodyweight of individual mice
in each group from day 7 (start of dietary restriction) and day 21 (after 14 days of dietary restriction). HGA, homogentisic acid; HPLA,
4-hydroxyphenyllactic acid; HPPA, 4-hydroxyphenylpyruvic acid; NTBC, nitisinone. Error bars represent SEM. One-way ANOVA (Tukey post-
hoc) significance: *P < .05; **P < .01; ***P < .001
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FIGURE 3 Dietary restriction of phenylalanine in NTBC-treated AKU mice. A, shows when blood samples were taken and when diet
conditions were altered. B, shows the plasma metabolite levels before NTBC treatment (all mice; n = 24), after 1 week of NTBC treatment (all
mice; n = 24), then after 3 (n = 6) and 14 (n = 6) days of diet phenylalanine restriction. C, shows the change in bodyweight of individual mice in
each group from day 7 (start of dietary restriction) and day 14 (after 7 days of dietary restriction). HGA, homogentisic acid; HPLA,
4-hydroxyphenyllactic acid; HPPA, 4-hydroxyphenylpyruvic acid; NTBC, nitisinone. Error bars represent SEM. One-way ANOVA (Tukey post-
hoc) significance: *P < .05, **P < .01, ***P < .001
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acid (HPLA) increased 19-fold from 2.0 ± 0.2 to
38.6 ± 3.0 μmol/L.
3.2 | Tyrosine/phenylalanine dietary
restriction
Nitisinone-treated AKU mice were fed a tyrosine and
phenylalanine-free diet, with phenylalanine supplemented
into the drinking water (5-1.25 mg/mL). The control group
remained on a normal diet. Blood samples were taken
according to the scheme in Figure 2A. Three days after die-
tary restriction, tyrosine was reduced from 813.3 ±
37.6 μmol/L (all groups, n = 24; Figure 2B) in a dose
responsive manner to 389.3 ± 42.3, 274.8 ± 6.3, and
144.3 ± 13.0 μmol/L in the 5, 2.5, and 1.25 mg restricted
groups, respectively. After 14 days of restriction, these
reductions were maintained. All comparisons to the control
group at both 3 and 14 days were significant (P < .001).
After 3 days of dietary restriction, significant reductions
in phenylalanine, HGA, HPPA and HPLA were present,
however the dose response was not as clear in these metabo-
lites (Figure 2B). After 14 days of dietary restriction, only
HGA and HPLA showed significant reductions compared to
the control group.
A second tyrosine/phenylalanine dietary restriction study
(data not shown) was carried out, with lower doses of phe-
nylalanine supplementation in the water (0.625, 0.3125, and
0 mg/mL). Further restriction of phenylalanine however did
not result in lower plasma tyrosine concentrations than those
shown in Figure 2, at both 3 and 4 days of restriction. No
significant weight changes were seen between any of the
groups at 4 days of restriction.
3.3 | Phenylalanine only dietary restriction
Nitisinone-treated AKU mice were fed a phenylalanine-free
diet with normal tyrosine, with phenylalanine supplemented
in drinking water (2.5-0 mg/mL). The control group
remained on a normal diet. Blood samples were taken
according to the scheme in Figure 3A. Plasma tyrosine was
63.5 ± 2.7 μmol/L pre-nitisinone and increased to
748.9 ± 26.8 μmol/L post-nitisinone (n = 24, all groups,
Figure 3B). After 3 days of phenylalanine restriction, tyro-
sine levels were 757.3 ± 54.9, 533.2 ± 28.8, and
656.2 ± 69.6 μmol/L, with only the latter two groups,
(0.625 mg/mL and phenylalanine-free), being significantly
different to control (P < .001 and P = .014, respectively).
After 7 days of dietary restriction, none of the restricted
groups had significantly lower tyrosine compared with the
control group.
Significant reductions in plasma phenylalanine were seen
at both 3 days (all groups P < .001 compared with control)
and after 7 days (0.625 mg/mL and phenylalanine-free, both
P < .001 compared with control; 2.5 mg/mL not signifi-
cantly different, P = .065) of phenylalanine dietary restric-
tion. HPLA demonstrated significant differences after 3 days
in the 0.625 mg/mL and phenylalanine-free groups however
these significant differences were not maintained after
7 days. HGA showed significant differences after 7 days of
dietary restriction in all the restricted groups however these
differences were not seen after 3 days. HPPA was not signif-
icantly reduced in the restricted groups compared with con-
trol, at neither 3 nor 7 days of dietary restriction.
3.4 | Body weight
The extent of tyrosine/phenylalanine dietary restriction (%)
in these studies was based upon daily food and water intake
values for mice weighing 30 g. At day 7 when dietary
restriction was implemented, the mean body weight of all
mice (n = 24) was 29.8 g (23.5-35.7 g) and 30.0 g
(23.7-37.1 g) in the tyrosine/phenylalanine-free and phenyl-
alanine only-free diet studies respectively.
Individual body weight was monitored over the duration
of dietary restriction. At 14 days of restriction in the
tyrosine/phenylalanine-free diet study, the restricted groups
showed no significant change in body weight (Figure 2C)
compared to the control group (P = .841).
Figure 3C shows the changes in body weight after 7 days
of restriction in the phenylalanine only diet study. One-way
ANOVA demonstrated a significant difference in weight
change between the groups (P = .014), with differences
found between the 2.5 mg/mL group compared with the
0.625 mg/mL (P = .023) and phenylalanine-free (P = .021)
groups (post-hoc Tukey test). None of the restricted groups
however showed weight changes significantly different to
the control group.
3.5 | NAC dietary intervention in AKU
patients
Average estimated protein intake from 7-day food diaries in
all AKU patients attending the NAC was 1.1 g protein/kg
bodyweight/day at baseline visit 1 (unpublished data) before
any intervention, which is comparable with the general pop-
ulation (NDNS2016). With nitisinone, dietary protein intake
is restricted to a recommended minimum level of 0.75 g
protein/kg bodyweight/day (SACN/COMA2008/2017), with
additional metabolic requirements provided by prescribed
tyrosine/phenylalanine-free amino acid supplements in some
patients.
Overall, significant reductions in serum tyrosine (Figure 4)
were seen in the 10 NAC patients observed (P = .002; two-
tailed Wilcoxon's signed rank test), with four patients
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reducing serum tyrosine <700 μmol/L. Three patients
(Figure 4, dashed lines) reduced serum tyrosine (mean[range])
by 22 [18-30]% by advised protein restriction alone; the other
seven patients required a combination of reduced protein
intake with tyrosine/phenylalanine-free supplements to
achieve a 33 [8-62]% reduction. The initial tyrosine value for
patients using amino acid supplements was with dietary
restriction alone, with subsequent values using a combination
of reduced protein intake and amino acid supplementation.
Across all 10 patients and all sample time points, phenylala-
nine (mean[range]) was 57 [38-108] μmol/L.
4 | DISCUSSION
The treatment of AKU with the HGA-lowering drug
nitisinone has proven to be effective at reducing HGA.24
However, data from clinical trial8 and off-label prescription
use at the NAC21 clearly demonstrate concomitant elevation
of tyrosine. Tyrosinemia can cause eye and skin keratopathy
in a minority of patients requiring a lower dose or cessation
of nitisinone, or a strict low protein diet, to resolve symp-
toms. Low-dose nitisinone, ranging from 0.5 to 2 mg daily,
has caused eye complications in five reported AKU patients
to date.11,12,25,26 Attempting to restrict dietary tyrosine and
phenylalanine consumption, while taking nitisinone to keep
HGA low, is the most logical approach to combat
tyrosinemia. A protein restricted diet however proves very
difficult to maintain and often causes keratopathy to return
when not adhered to.12 Therefore, finding an alternative
strategy to reduce dietary uptake of tyrosine and/or phenylal-
anine would allow nitisinone-treated AKU patients to con-
sume a normal protein diet. Before such strategies are
investigated, the findings of this paper has showed that
reducing dietary tyrosine/phenylalanine is effective at reduc-
ing tyrosine in AKU mice, with similar observational evi-
dence that lowering tyrosine via dietary intervention in
patients is achievable, therefore establishing a proof of prin-
ciple for targeting dietary tyrosine/phenylalanine in patients
who are on nitisinone.
Tyrosine threshold recommendations with nitisinone
treatment, which are often arbitrary, vary in the literature. In
HT-1 children <12 years, the recommended tyrosine level is
200 to 400 μmol/L, with concentrations after this age
allowed to rise, with eye complications experienced
>800 μmol/L.16 Another HT-1 review of 22 centers treating
patients aged 0 to 24 years found maximum acceptable tyro-
sine levels to be 200 to 800 μmol/L, with 400 μmol/L deter-
mined to be a safe and feasible target.17 A report of an adult
AKU patient who experienced eye keratopathy while receiv-
ing low-dose nitisinone (0.5-1.5 mg daily) suggests a target
tyrosine of <600 μmol/L,11 while a more recent NAC publi-
cation suggests <500 μmol/L is acceptable.24 NAC tyrosine
thresholds are designed to fit a dietetic care plan, that aims
to reduce serum tyrosine in order to prevent symptomatic
keratopathy, with systematic removal of dietary protein,
while taking into account compliance difficulties experi-
enced in patients.
In this study, the mouse tyrosine/phenylalanine-free diet
clearly showed a dose-responsive reduction in plasma tyro-
sine, with all groups reaching <400 μmol/L. The least
restricted group (5 mg/mL) reduced tyrosine to 389 μmol/L
at 3 days, achieved with approximately 68% phe-
nylalanine/no tyrosine. We also showed evidence that
human patients on nitisinone can reduce serum tyrosine with
dietary intervention. Tyrosine was significantly lowered
either by a low protein diet alone or in combination with pre-
scribed tyrosine/phenylalanine-free amino acid supplementa-
tion. Although four of 10 patients achieved tyrosine
<700 μmol/L, tyrosine was greatly reduced in some patients,
notably from 1084 to 762 μmol/L, and from 1217 to
859 μmol/L. Of the four patients that reduced tyrosine below
700 μmol/L, only one patient achieved this with dietary
advice alone; the other three patients used amino acid sup-
plementation. Prior to nitisinone, most adult AKU patients
will have consumed a normal protein diet throughout their
life, therefore adaption to dietary changes can be difficult,
especially in the absence of tyrosine-related keratopathy
where no benefit is perceived.
The NAC patient data were not collected as a controlled
trial, but as an observational study where patients are only
FIGURE 4 Serum tyrosine from 10 AKU patients receiving
nitisinone attending the National Alkaptonuria Centre. All 10 patients
had tyrosine >700 μmol/L. Both dietary advice (restriction of dietary
protein to a recommended minimum level of 0.75 g protein/kg
bodyweight) (n = 3) and dietary advice in combination with
tyrosine/phenylalanine-free amino acid supplements (n = 7) reduced
serum tyrosine. Initial tyrosine concentrations in the group using amino
acid supplements were measured after dietary advice alone, with
subsequent tyrosine concentrations measured after a combination of
dietary advice and amino acid supplement use
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advised to restrict their protein intake, therefore strict moni-
toring of compliance and protein intake was not carried out.
After specialist advice, patients were responsible for
restricting dietary protein in their daily lives, with guidance
from the dietician if needed. Progress with dietary compli-
ance is a long-term iterative process, since achieving long-
term, sustained behavior change in adults is a recognized
national dilemma. Compliance is the most likely reason that
only one of 10 NAC patients achieved <500 μmol/L tyro-
sine and is why mice were used for the restriction experi-
ments reported here. The diets of mice are easy to control, in
addition to eliminating other confounding factors such as
lifestyle, exercise, mobility, and disease severity differences.
The mouse data provides evidence that dietary restriction of
tyrosine/phenylalanine can effectively reduce nitisinone-
induced tyrosinemia, providing the rationale to carry out a
controlled trial in human AKU patients, where lower tyro-
sine levels than those presented here would be expected.
In mice, the dose response observed due to phenylalanine
supplementation, in the absence of tyrosine (Figure 2), sug-
gests that tyrosine derived from phenylalanine is important
to target. However, phenylalanine only restriction was inef-
fective at lowering nitisinone-induced tyrosinemia, even
with complete phenylalanine restriction (Figure 3). This is
an important consideration as emerging experimental and
dietary phenylalanine-lowering strategies for the metabolic
disease phenylketonuria (OMIM #261600) may have been
beneficial for nitisinone-induced tyrosinemia if phenylala-
nine restriction alone had proven effective. Such strategies
include enzymatic phenylalanine degradation by exogenous
phenylalanine ammonia lyase enzyme, diets supplemented
with naturally occurring glycomacropeptide (GMP) protein
that is naturally low in phenylalanine instead of synthetic
amino acid foods, and genetically modified probiotics that
target phenylalanine-degradation in the intestine.27,28
Due to phenylalanine being an essential amino acid, its
restriction alone could lead to inadequate protein turnover,
with the balance of catabolism/anabolism disrupted, causing
a loss of lean mass.29 Although not significantly different to
the control group in the phenylalanine only restriction study,
there was a significant body weight reduction in the
phenylalanine-free and 0.625 mg/mL groups compared to
the 2.5 mg/mL group (Figure 3) at 7 days. This weight loss
was seen in the presence of tyrosine, suggesting that phenyl-
alanine restriction could lead to catabolism, therefore
targeting tyrosine would be more desirable. At 14 days of
restriction, no significant weight changes were seen in
Figure 2 in which tyrosine was absent and phenylalanine
was partially present.
It is essential to balance lowering protein intake in order
to lower tyrosine, with maintaining a healthy weight and
muscle mass, since catabolism itself provides residual
tyrosine. During routine NAC visits, anthropometric data
such as grip, mid upper arm circumference, and bio-
impedance data such as lean mass and fat mass, is collected
to provide sequential evidence of body composition trends
to minimize risk of catabolism. These parameters were not
investigated in the AKU patients presented in Figure 4, as
less than half of the tyrosine concentrations were measured
at a routine (yearly) NAC visit, where such anthropometric
data is collected. These parameters are worthy of investiga-
tion in both mice and humans in the future.
In addition to decreased tyrosine, other metabolic
improvements were observed with dietary restriction in
mice. HGA, which is lowered with nitisinone treatment, was
then significantly lowered in the restricted groups compared
to the control in the tyrosine/phenylalanine-free study. Both
HPPA and HPLA in mice, which were elevated with
nitisinone as recently shown in human AKU patients,30 were
significantly reduced compared to the control with restric-
tion. Although the effect of elevated HPPA and HPLA is
unknown, reducing them back toward normal physiological
levels would be desirable. Phenylalanine in mice was signifi-
cantly reduced after 3 days in the tyrosine/phenylalanine
restriction study, but this was not maintained to 14 days. In
human NAC patients, phenylalanine levels were within the
normal reference range.
Nitisinone is a lifelong treatment for AKU and is associ-
ated with hypertyrosinemia. Removal of tyrosine/phenylala-
nine, but not phenylalanine alone, from the diet of mice is
effective at reducing nitisinone-induced tyrosinemia. Protein
restriction coupled with tyrosine/phenylalanine-free amino
acid supplementation was able to reduce tyrosine levels in
patients observed at the NAC, although these reductions
were greater in mice, most likely owing to patient compli-
ance. A controlled trial in AKU patients would likely see
results similar to the mouse data shown here. We suggest
that strategies reducing tyrosine uptake from the intestine,
such as degradation of tyrosine by an exogenous enzyme or
a tyrosine-specific binder that prevents uptake into the circu-
lation, that allow a normal protein diet to be consumed,
could be investigated not only for nitisinone-treated AKU
patients, but also for nitisinone-treated HT-1 patients.
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